ArticleBMC psychology2025
Increased level of serum asymmetric dimethylarginine in individuals with more severe cognitive impairment, as evaluated using Montreal Cognitive Assessment instead of Mini-Mental State Examination.
Article in BMC psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThis study aimed to explore the link between cognitive impairment and levels of asymmetric dimethylarginine (ADMA).
methodsThe study included 172 patients from the Department of Geriatrics and Neurology at the Second Affiliated Hospital of Harbin Medical University. The enrollment period spanned from October 2013 to July 2014. To assess their cognitive function, we used the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). Additionally, automatic biochemical analyzers were employed to measure various biochemical blood indexes, while enzyme-linked immunosorbent assay was used to determine the serum ADMA concentrations.
resultsThe participants were categorized into four groups based on the MMSE scale, which reflects cognition (higher scores indicating better cognitive function), and five groups based on the MoCA scale, which also measures cognition (higher scores indicating better cognitive function). Various factors were analyzed for their statistical significance in relation to different cognitive impairment groups determined by each scale. Regarding the MoCA scale, the following factors were found to be statistically significant: Age (P = 0.0001), systolic blood pressure (P = 0.0261), ALT (P = 0.0104), AST (P = 0.0106), endogenous creatinine clearance (P = 0.0006), and serum ADMA concentration (P = 0.0383). For the MMSE scale, the following factors showed statistical significance: Age (P = 0.0008), ALT (P = 0.0002), AST (P = 0.0088), CRP (P = 0.0407), and endogenous creatinine clearance (P = 0.0027). Interestingly, as the scores on the MoCA scale decreased, the serum ADMA concentration increased (P=0.0383), but this trend was not observed in the groups classified based on the MMSE scale (P > 0.05).
conclusionThe level of sensitivity measured by the MoCA scale indicated the presence of initial cognitive dysfunction. The extent of cognitive impairment showed a direct correlation with ADMA levels, indirectly implying a connection between impaired endothelial function and cognitive dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.